United States· US:84230-551_2a019a0b-29c4-d5ef-e063-6394a90ad52f
Mulpleta
A lusutrombopag product containing lusutrombopag, registered in United States by VANCOCIN ITALIA SRL. The same ATC class is registered in 7 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Lusutrombopag is registered in 7 of 19 countries.
Countries holding a registration under ATC B02BX07 (lusutrombopag), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 4 of them publish a price we can compare per daily dose
Lusutrombopag · ATC B02BX07
7 / 19 countries
- Belgiumprice
- Finlandprice
- Ireland
- Japan
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- LUSUTROMBOPAG
- Manufacturer
- VANCOCIN ITALIA SRL
- Country
- United States (US)
- ATC code
- B02BX07
- ATC class
- Lusutrombopag
- Defined daily dose
- 3 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1184230551071 DOSE PACK in 1 CARTON (84230-551-07) / 7 TABLET, FILM COATED in 1 DOSE PACK
- ndc1184230-551-07
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
164 interactions on record for lusutrombopag.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lusutrombopag · interactions on record
164 records
- 2 severe
- 162 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- RolapitantA04AD14moderate
- FidaxomicinA07AA12moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lusutrombopag in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/719412ec-fb6a-43ba-b381-dcafc2428dc2 GET /v1/drugs/719412ec-fb6a-43ba-b381-dcafc2428dc2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "3",
"substance": "LUSUTROMBOPAG",
"productndc": "84230-551",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA210923",
"marketing_category": "NDA"
}See everything about lusutrombopag.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.